Concept Phase Sample Clauses

Concept Phase a. Prepare an analysis of the site and, in the case of the rehabilitation of an existing building, the existing condition of the building, including, but not limited to, determining the location, measurement and other essential data of existing architectural, equipment, structural, mechanical, electrical and utility features, and submit a report to the Fund setting forth such analysis and confirming that the data available is sufficient to proceed with the design of the project. Provide additional information reasonably determined by the Fund to be necessary or desirable, such as topography, soil data, and municipal agency and utility company projects and/or a plan for accessing such information.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Concept Phase a. Data Collection – Obtain as-builts, topographic survey, other drawings and reports from the County and adjacent developer pertinent to the site.
Sample 1Sample 2
Concept Phase. Per the Memorandum of Understanding, all ODOT and PWB waterline initial design and review costs during the Concept Phase, prior to June 14, 2021, and consultant work included in contract amendment #1, will be shared equally between Agency and ODOT. The total cost of the Concept Phase is $411,000. Agency shall pay ODOT $126,500 to complete Agency’s 50% share. Breakdown is as follows:
Sample 1Sample 2
Concept Phase. To develop a sufficient level of understanding for the equipment under control (EUC) and its environment to enable the other safety lifecycle activities to be carried out satisfactorily. • Overall Scope Definition. To determine the boundary between the EUC and EUC control system (ECS), and to specify the scope of the hazard and risk analysis.
Sample 1
Concept Phase. The Concept Phase (see Figure 20) comprises the Item Definition, the Hazard and Risk Analysis and the Functional Safety concept. All the activities emphasized in red are security related activities and thereby form an extension to the life cycle defined by the ISO 26262. act Activ ity Hazard and Risk Analysis Describe Hazardous Events Item Definition Determine Criticality Level (ASIL) HAZOP method Derive Fuctional Requirements Derive Safety Goals Identify Malfunctions Derive Functional Safety Derive Functional Security Requirements Requirements Identify Functions Functional Description Identify Security Violations Operational Situations Interference Analysis Threat Analysis Describe Threats Security Violations Determine Criticality Level Security Goals Derive Security Goals Functional Security Requirements Functional Safety Requirements Safety Goals Malfuctions Qualitative FTA Figure 20 – Safety and security activities of the Concept Phase The Item Definition should collect all information relevant to the safety and security analysis and design for the item:  purpose and description,  function(s) and relations between functions,  requirements for each function,  draft architecture/outline,  additional nonfunctional constraints,  borders or interfaces to other items/systems,  legal requirements, whereby an item is a system that implements a function at the vehicle level. An important aspect is the identification of some malfunctioning behaviour of the considered system, which is later considered during Hazard and Risk Analysis. Potential malfunctions can be identified during Item Definition using HAZOP analysis [54]1. Analogously the Item Definition activity is also extended by a security related activity that identifies possible security violations. As a result of the Item Definition a functional description of the item, a set of malfunctions and a set of security violations are defined. The hazard and risk analysis consists of three fundamental steps. The situation analysis and hazard identification considers the potential malfunctioning behaviour of the item in combination with certain operational situations that could lead to a hazardous event. These events are classified in the next step, the hazard classification, in respect to their severity (S), their exposure (E) and their controllability in order to determine the automotive safety integrity level (ASIL). The third step is to derive the safety goals that have to be fulfilled in order to prev...
Sample 1
Concept Phase. Price: The concept phase is quoted for *** ******.
Sample 1
Concept Phase. During this phase, the Parties will validate the standard P2P processes to be implemented and any unique Solectron requirement which might have to be taken into account.
Sample 1
AutoNDA by SimpleDocs
Concept Phase. The services called for in the Report Phase of this Agreement shall be completed concurrently with the preliminary design phase and five (5) copies of the Preliminary Study and Report shall be submitted within 30 consecutive calendar days following the written authorization from the Owner for the Consultant to proceed. The time frame set forth in the written authorization from the Owner for the Consultant to proceed.
Sample 1
Concept Phase. Students propose solutions - students meet as a full group to discuss various marketing solutions - students to determine which group will be responsible for which elements - students to propose timeline for competition of elements - proposed budget matching marketing elements/timeline - proposal to be approved/adjusted by faculty Weeks 4 - 6
Sample 1

Related to Concept Phase

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Inventions, etc The Executive hereby sells, transfers and assigns to the Company or any of its subsidiaries or affiliates or to any person or entity designated by the Company all of the entire right, title and interest of the Executive in and to all inventions, ideas, disclosures and improvements, whether patented or unpatented, and copyrightable material, made or conceived by the Executive, solely or jointly, during his employment by the Company which relate to methods, apparatus, designs, products, processes or devices, sold, leased, used or under consideration or development by the Company or any of its subsidiaries or affiliates, or which otherwise relate to or pertain to the business, functions or operations of the Company or any of its subsidiaries or affiliates or which arise from the efforts of the Executive during the course of his employment for the Company. The Executive shall communicate promptly and disclose to the Company, in such form as the Company requests, all information, details and data pertaining to the aforementioned inventions, ideas, disclosures and improvements; and the Executive shall execute and deliver to the Company such formal transfers and assignments and such other papers and documents as may be necessary or required of the Executive to permit the Company or any of its subsidiaries or affiliates or any person or entity designated by the Company to file and prosecute the patent applications and, as to copyrightable material, to obtain copyright thereof. Any invention relating to the business of the Company or any of its subsidiaries or affiliates and disclosed by the Executive within one year following the termination of his employment with the Company shall be deemed to fall within the provisions of this paragraph unless proved to have been first conceived and made following such termination. The foregoing requirements of this Section 7(d) shall not apply to any invention for which no equipment, supplies, facility or trade secret information of the Company was used and which was developed entirely on the Executive’s own time, and (i) which does not relate directly to the Company’s, or any of its subsidiaries’ or affiliates’, business or to the Company’s, or any of its subsidiaries’ or affiliates’, actual or demonstrably anticipated research or development, or (ii) which does not result from any work the Executive performed for the Company or any of its subsidiaries or affiliates.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Project Scope The physical scope of the Project shall be limited to only those capital improvements as described in Appendix A of this Agreement. In the event that circumstances require a change in such physical scope, the change must be approved by the District Committee, recorded in the District Committee's official meeting minutes, and provided to the OPWC Director for the execution of an amendment to this Agreement.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Creative Work The Executive agrees that all creative work and work product, including but not limited to all technology, business management tools, processes, software, patents, trademarks, and copyrights developed by the Executive during the term of this Agreement, regardless of when or where such work or work product was produced, constitutes work made for hire, all rights of which are owned by the Employer. The Executive hereby assigns to the Employer all rights, title, and interest, whether by way of copyrights, trade secret, trademark, patent, or otherwise, in all such work or work product, regardless of whether the same is subject to protection by patent, trademark, or copyright laws.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Project Plan Development of Project Plan Upon the Authorized User’s request, the Contractor must develop a Project Plan. This Project Plan may include Implementation personnel, installation timeframes, escalation procedures and an acceptance plan as appropriate for the Services requested. Specific requirements of the plan will be defined in the RFQ. In response to the RFQ, the Contractor must agree to furnish all labor and supervision necessary to successfully perform Services procured from this Lot. Project Plan Document The Contractor will provide to the Authorized User, a Project Plan that may contain the following items: • Name of the Project Manager, Contact Phone Numbers and E-Mail Address; • Names of the Project Team Members, Contact Phone Numbers and E-Mail Address; • A list of Implementation milestones based on the Authorized User’s desired installation date; • A list of responsibilities of the Authorized User during system Implementation; • A list of designated Contractor Authorized Personnel; • Escalation procedures including management personnel contact numbers; • Full and complete documentation of all Implementation work; • Samples of knowledge transfer documentation; and • When applicable, a list of all materials and supplies required to complete the Implementation described in the RFQ. Materials and Supplies Required to Complete Implementation In the event that there are items required to complete an Implementation, the Contractor may request the items be added to its Contract if the items meet the scope of the Contract. Negotiation of Final Project Plan If the Authorized User chooses to require a full Project Plan, the State further reserves the right for Authorized Users to negotiate the final Project Plan with the apparent RFQ awardee. Such negotiation must not substantively change the scope of the RFQ plan, but can alter timeframes or other incidental factors of the final Project Plan. The Authorized User will provide the Contractor a minimum of five (5) business days’ notice of the final negotiation date. The Authorized User reserves the right to move to the next responsible and responsive bidder if Contractor negotiations are unsuccessful.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Time is Money Join Law Insider Premium to draft better contracts faster.